Astana, Kazakhstan, 05 August 2025 — MicroPort® Endovastec™ announced the first commercial implantation of its Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™) in Kazakhstan. This marks the latest addition to the company’s product portfolio in this region, following of its Castor™ Branched Aortic Stent Graft System.
The procedure was performed by Dr. Aripov Marat and his team at the Department of Cardiothoracic Surgery and Radiology at the Corporate Fund University Medical Center Hospital.
The patient, a 63-year-old male, was diagnosed with an abdominal aortic aneurysm, complicated by severe calcification at the iliac artery access site. Based on preoperative imaging and measurements, Dr. Marat and his team selected the Minos™ system as part of a tailored treatment plan.
Postoperative imaging confirmed smooth stent deployment, with the stent maintaining its intended configuration and sealing, contributing to a successful outcome.
Minos™ is MicroPort® Endovastec™’s flagship product in abdominal aortic intervention. It is designed for the endovascular treatment of abdominal aortic aneurysms with a proximal neck length of ≥15mm. It is the first China developed product to reduce the outer sheath diameter of the delivery system to 14F, significantly lowering the requirements for vascular access during surgery. Featuring a three-piece structure design, it can be flexibly assembled inside the body, maximizing coverage of the diseased area. It offers unique advantages in treating complex abdominal aortic aneurysms, especially in cases involving tortuous necks, short necks, or narrowed entry arteries.
Minos™ is currently in clinical use in over 1,000 hospitals across more than 20 countries, with growing adoption supported by physician feedback and ongoing clinical experience.
About MicroPort® Endovastec™
Founded in 2012, MicroPort® Endovastec™ (Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), an associated company of MicroPort® (MicroPort Scientific Corporation, HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. MicroPort® Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, and drug-coated PTA balloon catheters. MicroPort® Endovastec™ breaks barriers and accelerates innovation to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping all lives, and to build a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.
More information is available at: www.endovastec.com/en